Minimal impact
Mixed findings for benefits of tamper-resistant oxycodone The introduction of tamper-resistant oxycodone formulations in Australia in early 2014 has led to little change in the levels of population-level opioid use …
Patients in pain
Pharmacy patients are complaining of being “treated like drug addicts” as codeine change awareness spreads, say extended hours pharmacists With the codeine upscheduling deadline of 1 February looming, the Extended …
Vale Geoff Vaughan
Former Victorian pharmacy dean and Australian Rugby international dies aged 84 Dr Geoffrey Vaughan AO, who was Dean of the Victorian College of Pharmacy (“VCP”) from 1979 to 1986, passed …
The holiday season is upon us
It’s farewell to 2017 from the team at AJP Daily This newsletter is the final edition of AJP Daily for 2017. The newsletter will resume on Tuesday 9 January, with …
2017: Year in review
It was a year which began for pharmacy in discussion of the fate of codeine, staff pay issues and a review which threatened to destabilise the community pharmacy model And …
Cabinet changes
New Ministers appointed to health, business portfolios Some new faces will be occupying ministerial positions in portfolios of relevance to community pharmacy after Prime Minister Malcolm Turnbull announced his Cabinet …
Pharmacist steps down from NPS role
Lynn Weekes to leave NPS after two decades at the helm The Board of NPS MedicineWise has announced that Dr Lynn Weekes AM has resigned as the organisation’s CEO after …
The division of labour
Opinions and concerns of pharmacy owners and employees now more divergent than ever before There is now a wider gulf in the views of pharmacy owners and employee pharmacists than …
Take three lattes a day for that
Worried about the level of your caffeine intake? Well, new research has indicated that 3-4 cups per day may be doing more good than harm, except during pregnancy UK researchers …
Hit to trading terms
Wholesalers forced to act in the wake of direct distribution defections The recent moves by manufacturers AstraZeneca and Amgen to a direct distribution model are being blamed for driving full-line …

